Healthcare-Associated Infections (HAI) and Antimicrobial Use Prevalence Survey
The primary objectives of the HAI/antimicrobial use prevalence survey effort are to:
- Estimate HAI prevalence in a large sample of inpatients in U.S. acute healthcare facilities
- Determine the distribution of HAI by pathogen (including antimicrobial-resistant pathogens) and major infection site
- Estimate the prevalence and describe the rationale for antimicrobial use in a large sample of inpatients in U.S. acute healthcare facilities.
Goals and Objectives
- Estimate of the prevalence of HAIs aggregated across participating hospitals, and distribution of HAIs by major infection site and pathogens (including antimicrobial-resistant pathogens).
- Estimate of the prevalence of antimicrobial use (expressed as percentage of total inpatients receiving an antimicrobial agent) aggregated across participating hospitals.
- Estimate of the distribution of antimicrobial use by drug type, rationale and therapeutic site.
Measurements of the magnitude and types of HAIs occurring hospital-wide are needed to inform decisions by local and national policy makers and by hospital infection control personnel regarding appropriate targets and strategies for HAI prevention. Previous prevalence surveys were conducted in the 1970s, and in the 1980s a national database into which hospitals could record infections was established. In 2009 the CDC conducted a single-city pilot Point Prevalence survey to assess the feasibility and methodology of conducting a survey on a larger scale. The URMC Emerging Infection Program participated in Phase II (limited roll-out) and Phase III of the Point Prevalence Survey in 2010 and 2011.
The 2011 HAI and Antimicrobial Use Prevalence Survey was conducted at 23 hospitals in nine counties in Central and Western New York. To assess the prevalence of HAIs and antimicrobial use in a large sample of U.S. acute care inpatients, teams were assembled to perform data collection on a sample of eligible, hospitalized patients on a single day designated as the survey date. Teams collected limited demographic data and information on risk factors and antimicrobial use. Medical records of patients who were administered or scheduled to be administered at least one antimicrobial agent on the survey date or the calendar day prior to the survey date (with a qualification for patients on hemodialysis or peritoneal dialysis) were reviewed in detail by EIP staff members to document antimicrobial use. Medical records of patients who were determined by EIP staff members to have received at least one antimicrobial agent for treatment of active infection, or for whom the rationale for antimicrobial use is not documented, will undergo additional detailed review to identify active HAIs.
Results from the Phase I Pilot Survey:
Infection Control and Hospital Epidemiology